A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.

ABSTRACT: A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen. Safety, immunogenicity, and VE of a three-dose regimen were assessed in adults in Balonghin, Burkina Faso in a two-component study: an open-label dose escalation trial with 32 participants followed by a double-blind, randomized, placebo-controlled trial (RCT) with 80 participants randomized to receive three doses of 2.7 × 10⁶ PfSPZ (N = 39) or normal saline (N = 41) just before malaria season. To clear parasitemia, arte

SUBMITTER: Sirima SB 

PROVIDER: S-EPMC10041996 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature